PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

BACKGROUND: Several mechanisms including abnormal activation of PI3K-AKT-mTOR pathway have been proved to generate acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). In this study, we investigated the genomic charac...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wenfeng, Huang, Yihua, Gu, Weiguang, Gan, Jiadi, Wang, Wenjing, Zhang, Shiyue, Wang, Kai, Zhan, Jianhua, Yang, Yunpeng, Huang, Yan, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481581/
https://www.ncbi.nlm.nih.gov/pubmed/32953503
http://dx.doi.org/10.21037/tlcr-20-141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481581/
https://www.ncbi.nlm.nih.gov/pubmed/32953503
http://dx.doi.org/10.21037/tlcr-20-141

Ejemplares similares